Overexpression of FOXM1 in high-grade ovarian cancer patients was shown to correlate with resistance against platinum-agents and poor prognosis, with patients quickly building up resistance to standard therapy which was also observed with ovarian cancer cell lines in vitro [23,49,50,51]. Here, FOXM1 is linked to ovarian carcinoma.